A call for the better utilization of physical activity and exercise training in the defense against cardiovascular disease

References

• Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
   PubMed Web of Science ®Google Scholar
• Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:1560–1566.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25):2889–2934.
   PubMed Web of Science ®Google Scholar
• Charansonney OL, Vanhees L, Cohen-Solal A. Physical activity: from epidemiological evidence to individualized patient management. Int J Cardiol. 2014;170(3):350–357.
   PubMed Web of Science ®Google Scholar
• Chomistek AK, Chiuve SE, Jensen MK, et al. Vigorous physical activity, mediating biomarkers, and risk of myocardial infarction. Med Sci Sports Exerc. 2011;43(10):1884–1890.
   PubMed Web of Science ®Google Scholar
• Kokkinos P, Myers J. Exercise and physical activity: clinical outcomes and applications. Circulation. 2010;122(16):1637–1648.
   PubMed Web of Science ®Google Scholar
• Zhang B, Kawachi E, Miura S et al. Therapeutic approaches to the regulation of metabolism of high-density lipoprotein. Novel HDL-directed pharmacological intervention and exercise. Circ J. 2013;77:2651–2663.
   PubMed Web of Science ®Google Scholar
• Stamatakis E, Hamer M, Primatesta P. Cardiovascular medication, physical activity and mortality: cross-sectional population study with ongoing mortality follow-up. Heart. 2009;95(6):448–453.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Brandrup-Wognsen G, Palmer MK, et al. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J Lipid Res. 2010;51(6):1546–1553.
   PubMed Web of Science ®Google Scholar
• Coen PM, Flynn MG, Markofski MM, et al. Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage. Metabolism. 2009;58(7):1030–1038.
   PubMed Web of Science ®Google Scholar
• Al Sifri SN, Almahmeed W, Azar S, et al. Results of the dyslipidemia international study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment. PLoS One. 2014;9(1):e84350.
   Google Scholar
• DuBroff R, de Lorgeril M. Cholesterol confusion and statin controversy. World J Cardiol. 2015;7(7):404–409.
   PubMed Web of Science ®Google Scholar
• Kokkinos PF, Faselis C, Myers J, et al. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet. 2013;381(9864):394–399.
   PubMed Web of Science ®Google Scholar
• Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373–418.
   PubMed Web of Science ®Google Scholar
• Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev. 2012;40(4):188–194.
   PubMed Web of Science ®Google Scholar
• Opie LH. Exercise-induced myalgia may limit the cardiovascular benefits of statins. Cardiovasc Drugs Ther. 2013;27(6):569–572.
   PubMed Web of Science ®Google Scholar
• Mascitelli L, Pezzetta F. Physical activity in statin-treated patients. Int J Cardiol. 2009;134(1):136–137.
   PubMed Web of Science ®Google Scholar
• Mikus CR, Boyle LJ, Borengasser SJ, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol. 2013;62(8):709–714.
   PubMed Web of Science ®Google Scholar
• Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127(1):96–103.
   PubMed Web of Science ®Google Scholar
• Sinzinger H, O’Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol. 2004;57(4):525–528.
   PubMed Web of Science ®Google Scholar
• Lee DS, Markwardt S, Goeres L, et al. Statins and physical activity in older men: the osteoporotic fractures in men study. JAMA Intern Med. 2014;174(8):1263–1270.
   Web of Science ®Google Scholar
• Bouitbir J, Charles A-L, Rasseneur L, et al. Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress. J Appl Physiol. 2011;111(5):1477–1483.
   PubMed Web of Science ®Google Scholar
• Meador BM, Huey KA. Statin-associated changes in skeletal muscle function and stress response after novel or accustomed exercise. Muscle Nerve. 2011;44(6):882–889.
   PubMed Web of Science ®Google Scholar
• Muraki A, Miyashita K, Mitsuishi M, et al. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance. J Appl Physiol. 2012;113(3):479–486.
   PubMed Web of Science ®Google Scholar
• Murlasits Z, Radák Z. The effects of statin medications on aerobic exercise capacity and training adaptations. Sports Med. 2014;44(11):1519–1530.
   PubMed Web of Science ®Google Scholar
• Traustadóttir T, Stock AA, Harman SM. High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults. Age (Dordr). 2008;30(4):283–291.
   PubMed Web of Science ®Google Scholar
• Chung J, Brass EP, Ulrich RG, et al. Effect of atorvastatin on energy expenditure and skeletal muscle oxidative metabolism at rest and during exercise. Clin Pharmacol Ther. 2008;83(2):243–250.
   PubMed Web of Science ®Google Scholar
• Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation. 2002;106(8): 1024–1028.
   PubMed Web of Science ®Google Scholar
• Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve. 2010;42(4):469–479.
   PubMed Web of Science ®Google Scholar
• Eijsvogels TM, Parker BA, Thompson PD. Statin and exercise prescription authors’ reply. Lancet. 2013;381(9878):1621.
   PubMed Web of Science ®Google Scholar
• Fiuza-Luces C, Garatachea N, Berger NA, et al. Exercise is the real polypill. Physiology (Bethesda). 2013;28(5):330–358.
   PubMed Web of Science ®Google Scholar
• Mascitelli L, Goldstein MR. Statin and exercise prescription authors’ reply. Lancet. 2013;381(9878):1622.
   PubMed Web of Science ®Google Scholar
• Mora S, Ridker PM. Justification for the use of statins in primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)—can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006;97(2):33–41.
   PubMed Web of Science ®Google Scholar
• Myers J, McAuley P, Lavie CJ, et al. Physical activity and cardiorespiratory fitness as major markers of cardiovascular risk: their independent and interwoven importance to health status. Prog Cardiovasc Dis. 2015;57(4):306–314.
   PubMed Web of Science ®Google Scholar
• Metkus TS Jr1, Baughman KL, Thompson PD. Exercise prescription and primary prevention of cardiovascular disease. Circulation. 2010;121(23):2601–2604.
   PubMed Web of Science ®Google Scholar
• Levinger I, Shaw CS, Stepto NK, et al. What doesn’t kill you makes you fitter: a systematic review of high-intensity interval exercise for patients with cardiovascular and metabolic diseases. Clin Med Insights Cardiol. 2015;9:53–63.
   PubMedGoogle Scholar
• Chow CK, Jolly S, Rao-Melacini P, et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation. 2010;121(6):750–758.
   PubMed Web of Science ®Google Scholar
• Juneau M, Hayami D, Gayda M, et al. Provocative issues in heart disease prevention. Can J Cardiol. 2014;30(12):S401–S409.
   Google Scholar
• Gielen S, Laughlin MH, O’Conner C, et al. Exercise training in patients with heart disease: review of beneficial effects and clinical recommendations. Prog Cardiovasc Dis. 2015;57(4):347–355.
   PubMed Web of Science ®Google Scholar